EUVIMEDEUVIMED entdecken
Crossref

Genetically predicted lipoprotein(a), first and recurrent venous thromboembolism, and coagulation proteins: evidence against causal relationships

Iyas Daghlas, Dipender Gill

Journal of Thrombosis and Thrombolysis · 10.11.2026

DOI: 10.1007/s11239-026-03430-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Thrombolysis, online erschienen am 10.11.2026. Verfasst von Iyas Daghlas und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, 400 Parnassus Ave, San Francisco, CA, 94143-…. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

CoagulationLipoprotein(a)Mendelian randomizationVenous thromboembolism

Autor:innen und Institutionen

  • Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, 400 Parnassus Ave, San Francisco, CA, 94143-0114, USA. iyas.daghlas@ucsf.edu.
  • Sequoia Genetics, London, UK.

Zitieren

APA

Daghlas, I., & Gill, D. (2026). Genetically predicted lipoprotein(a), first and recurrent venous thromboembolism, and coagulation proteins: evidence against causal relationships. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-026-03430-0

Vancouver

Daghlas I, Gill D. Genetically predicted lipoprotein(a), first and recurrent venous thromboembolism, and coagulation proteins: evidence against causal relationships. Journal of Thrombosis and Thrombolysis. 2026. doi:10.1007/s11239-026-03430-0

BibTeX
@article{Daghlas2026,
  author = {Daghlas, Iyas and Gill, Dipender},
  title = {Genetically predicted lipoprotein(a), first and recurrent venous thromboembolism, and coagulation proteins: evidence against causal relationships},
  journal = {Journal of Thrombosis and Thrombolysis},
  year = {2026},
  doi = {10.1007/s11239-026-03430-0}
}
Kostenlos starten →